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A b s t r a c t
Introduction: In March 2013, the European Association of Urology (EAU) 
released a  new edition of the guidelines on management of male lower 
urinary tract symptoms (LUTS), including benign prostatic obstruction. The 
objective of this study was to evaluate how well the EAU guidelines have 
been implemented in day-to-day practice by Polish urologists.
Material and methods: A  structured questionnaire, which explored how 
urologists diagnose and manage male lower urinary tract symptoms, was 
emailed to all certified, actively practicing urologists from a list provided by 
the Polish Urological Association.
Results: The questionnaire return rate was 33.7% (135/400). Overall, the me-
dian (quartile 1; quartile 3) frequency of correct answers was 65.0% (58.0%; 
69.0%). Analysis of the association of availability and acceptance of the EAU 
guidelines with question answers showed no pattern. A multivariate regres-
sion model showed a  positive correlation with regards to correct answers 
given in the survey and doctors’ participation in international congresses 
(p = 0.018, r = 0.181). Basket analysis showed the strongest association for 
those who failed to correctly answer the questions regarding diagnosis of 
LUTS and overactive bladder (OAB) (support = 27.41%, confidence = 86.05%).
Conclusions: Although there is a significant degree of adherence to the 2013 
EAU guidelines, some discrepancies between urologists’ practice and the rec-
ommendations regarding diagnosis and treatment of male LUTS do exist. The 
data obtained provide valuable benchmarks and also identify possible inter-
ventions that may improve the standard of care in this population of patients.
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Introduction
The knowledge about the natural history of benign prostatic hyperpla-
sia (BPH) has broadened immensely over the last 20 years. Consequently, 
the traditional notion that lower urinary tract symptoms are solely relat-
ed to BPH has changed. Accumulated evidence on multifactorial etiology 
of male LUTS has led most experts in the field to regard the entire urinary 
tract as a single functional unit [1, 2]. Evolution of a more complex ap-
proach to the pathogenesis and treatment of LUTS resulted in the formu-
lation of new, more contemporary European Association of Urology (EAU) 
guidelines on “management of non-neurogenic male LUTS” in 2011, and 
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their further modification in 2013: “management 
of male lower urinary tract symptoms, including 
benign prostatic obstruction” [3, 4]. These guide-
lines lay down advice on all aspects of assessment 
and management of LUTS, including conservative, 
medical and surgical options. 
In many European countries, the EAU guide-
lines have been adopted and implemented by 
national urological associations or, alternatively, 
serve as a basis for the formulation of their own 
national guidelines by others. In Poland, while 
several chapters of the EAU guidelines regarding 
oncological diseases of the urinary tract, as well 
as urinary incontinence, neurogenic lower urinary 
tract dysfunction and pain management, have 
been translated into Polish, others have been ac-
cepted as national guidelines without translation.
While the majority of the recommendations in 
the new 2013 edition of the EAU guidelines on the 
management of male LUTS have already been in 
place for some time and, therefore, have become 
common practice, there are still some new im-
portant aspects which require implementation 
in routine urological practice. At present, little is 
known about practice patterns of Polish urologists 
in the management of male lower urinary tract 
symptoms. Thus, to gain an insight into urologist 
awareness and approach of the management of 
LUTS, and in order to evaluate how well the EAU 
guidelines have been implemented in day-to-day 
practice, we performed a  nationwide survey on 
the current strategies used by Polish urologists in 
the diagnosis and management of male patients 
with lower urinary tract symptoms.
Material and methods
A  42-point questionnaire was developed us-
ing a critical assessment by colleagues within the 
authors’ departments, based on the EAU 2013 
guidelines entitled: “Management of male lower 
urinary tract symptoms (LUTS), including benign 
prostatic obstruction (BPO)” and following a thor-
ough literature review [4]. 
The study was conducted between April and 
July of 2013. The questionnaire was emailed to 
all certified, actively practicing urologists from the 
list provided by the Polish Urological Association. 
The respondents’ identity was kept anonymous. 
Participants received a  cover letter, which de-
scribed the evolution of concepts of the etiology 
of male LUTS and explained the aim of the survey. 
The questionnaire consisted of three parts. The 
questions in part one (16 questions) covered doc-
tors’ demographics, use of urological knowledge 
sources, as well as penetration, awareness and 
acceptance of the EAU 2013 guidelines. Part two 
was designed to determine urologists’ diagnostic 
pattern in patients with LUTS and overactive blad-
der (OAB) (10 questions), as well as the therapy of 
those same patients (16 questions) (Appendix 1). 
Statistical analysis
Pearson’s c2 test was used to analyze the associ-
ation between provision of correct and incorrect an-
swers to the survey questions by the doctors and the 
accessibility and acceptance of the EAU guidelines. 
Spearman’s correlation coefficient and multi-
variate logistic regression analysis were applied to 
determine the correlation of answering a question 
correctly and incorrectly with time since having 
completed the residency program in urology, num-
ber of urological journals to which the participant 
subscribed, number of national and internation-
al conferences attended, as well as being an EAU 
member. The Wald statistic was used to test the 
significance of the regression coefficient. 
The number of doctors who answered correctly 
within the four specific specialty knowledge do-
mains (diagnosis of LUTS and OAB, treatment of 
LUTS and OAB) was expressed in percentages, 
where a 60% cut off was considered satisfactory 
for diagnosis and treatment of LUTS. Since there 
was only one question regarding diagnosis of OAB 
and one about the treatment of OAB in the survey, 
a respondent was considered to pass those parts 
of the test if he/she answered them correctly. 
To determine whether choosing the wrong an-
swer within one knowledge domain increased the 
likelihood of answering incorrectly within other 
domains, the association rules analysis (a detailed 
version of market basket analysis) was performed. 
A  p value of < 0.05 was considered statistically 
significant. The Statistical Package for the Social 
Sciences (SPSS), version 19, was used for all sta-
tistical analyses.
Results
Of the 400 certified, actively practicing urologists, 
registered with the Polish Urological Association, 
136 returned the questionnaire. One was discarded 
because of incomplete details, leaving 135 (33.7%). 
Forty-three percent of respondents (58/135) had 
been certified urologists for more than 15 years, 
20% (27/135) for less than 5 years, 20% (27/135) 
had been practicing urology as specialists for 10 
to 15 years, and 17.0% (23/135) for 5 to 10 years. 
Urologists worked only in the outpatient department 
(OPD) in 50.4% of cases (68/135). The remainder 
(67/135) practiced in both a  urology department 
and an OPD. Fifty-seven percent of responding doc-
tors (77/135) worked in public outpatient clinics, and 
97% (131/135) provided services within a  private 
setting. The majority of urologists (74.8%, 101/135) 
regularly saw more than 20 patients in OPD clinics 
a  day, whereas 23.0% (31/135) and 2.2% (3/135) 
saw between 10 and 20, and less than 10 patients 
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per day, respectively. Urological journals, national 
and international urological conferences, informa-
tion provided by pharmaceutical company represen-
tatives, urological books, and discussion with col-
leagues served as a source of knowledge for 39.3% 
(53/135), 28.1% (38/135), 22.2% (30/135), 7.4% 
(10/135), and 2.9% (4/135) of respondents, respec-
tively. Only 40% (54/135) of doctors who completed 
the survey were members of the EAU. Although all of 
the respondents of the questionnaire were aware of 
the new 2013 version of the EAU guidelines on the 
management of male lower urinary tract symptoms, 
availability of the latest edition among EAU mem-
bers was 72.2% (39/135), whereas among the non-
EAU members, it was 65.4% (53/135). One hundred 
and four doctors who completed the questionnaire 
(77.0%) wished to have all chapters of the 2013 
EAU guidelines translated into Polish, 3.0% (4/135) 
would like to have only selected chapters translated, 
and only 20.0% (27/135) did not express the need 
for the translation. Complete and partial acceptance 
of the 2013 EAU guidelines among respondents was 
46.7% (63/135) and 52.6% (71/135), respectively. 
Only one doctor (0.7%) did not agree with the Eu-
ropean Association of Urology guideline recommen-
dations.
Adherence to the European Association 
of Urology guidelines in diagnosis of male 
patients with lower urinary tract symptoms 
and overactive bladder
The EAU guidelines recommend: “...Systemat-
ic diagnostic work-up should be done by history, 
validated symptom questionnaires (e.g. IPSS), 
both ideally proactively, physical examination, 
urinalysis, blood analysis, ultrasound (US) of the 
prostate, bladder and kidneys, uroflowmetry and 
US measurement of post-void residual urine, and 
bladder diary in cases of urinary frequency or noc-
turia...”
For the initial diagnostic evaluation of men with 
LUTS, a thorough urological history was found to 
be crucial among 97% of the respondents. Howev-
er, 44.4% of them did not routinely quantify symp-
toms with the International Prostate Symptom 
Score (IPSS). Similarly, the use of a bladder diary 
was not a common practice in 40.0% of doctors, 
and 8.1% would use it to evaluate the treatment 
outcome only.
The most frequently used tests during the 
initial work-up in men with LUTS in whom digi-
tal rectal examination revealed no abnormalities 
other than benign prostatic enlargement included 
prostate-specific antigen (PSA) evaluation (60.7%) 
and ultrasonographic examination of the urinary 
tract (28.1%). Urinalysis, blood biochemistry (se-
rum creatinine) and uroflowmetry were used by 
only 3.0%, 0.7% and 1.5% of respondents, respec-
tively (Figure 1).
The EAU guidelines recommend: “…Benign 
prostatic obstruction and detrusor overactivity are 
urodynamic diagnoses. Filling cystometry and pres-
sure-flow measurements are optional tests, usually 
indicated before surgical treatment in men who 
have a maximum flow rate (Qmax) > 15 ml/s…”
Sixty-three percent of respondents considered 
a maximum urine flow rate of less than 10 ml/s 
Figure 1. The most frequently used tests during initial work-up in men with LUTS, when digital rectal examination 
reveals no abnormalities other than benign prostatic enlargement
LUTS – Lower urinary symptoms, PSA – prostate specific antigen, USS – kidney, bladder and prostate ultrasound, IPSS – the 
International prostate Symptom Score.
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as indicative of bladder outlet obstruction, and 
24.4% of doctors held to a maximum flow of less 
than 15  ml/s as the diagnostic threshold. Size 
of the prostate was considered an important 
parameter in determining the method of surgi-
cal treatment in 43.7% of respondents. Howev-
er, 22.2% of doctors would consider size of the 
gland as an indication for treatment. To confirm 
the association between bladder outlet obstruc-
tion and benign prostate enlargement, 54.4% of 
urologists would perform an ultrasonographic ex-
amination of the urinary tract, 50.4% of doctors 
would perform uroflowmetry and 21% would do 
a filling cystometry and pressure-flow study. Size 
of the prostate determined on USS would well 
correspond with the presence of bladder outlet 
obstruction, as per the opinion of 42.2% of re-
spondents. In response to the question asking 
what information the urologist needed in order 
to diagnose overactive bladder in males, 68.9% 
of doctors replied that they required information 
obtained from the patient history and from ob-
jective tests, whereas 14.8% would base their 
diagnosis solely on a filling cystometry and pres-
sure-flow study.
Adherence to European Association of 
Urology guidelines in management of male 
patients with lower urinary tract symptoms 
and overactive bladder
The EAU guidelines recommend: “…Men with 
mild symptoms are suitable for watchful waiting. 
Men with LUTS should be offered lifestyle advice 
prior to or concurrent with treatment… a1-Block-
ers should be offered to men with moderate to 
mild lower urinary tract symptoms… a1-Blockers 
typically reduce the IPSS, after a run-in period in 
approximately 35–40%, and increase the maxi-
mum urinary flow rate by approximately 20–25%... 
a1-Blockers do not reduce prostate size and do not 
prevent acute urinary retention…”
Although 10% of respondents begin pharma-
cotherapy in patients with minimal or moderate 
LUTS and 86.7% of doctors prescribe drugs only 
in cases of severe symptoms, only 31.9% of urolo-
gists explain to patients that the aim of the treat-
ment is to reduce the frequency of LUTS, whereas 
51.9% of them tell men that it will prevent pos-
sible surgical intervention, and a  further 14.1% 
suggest delaying the surgery as a reason for intro-
ducing the medical approach. 
Of the a-blockers, tamsulosin and doxazosin 
were used most frequently, by 88.2% and 11.1% 
of urologists, respectively. Although 75.6% of 
respondents rightly expected improvement in 
LUTS when commencing therapy with a-blockers, 
23.7% prescribe this class of drugs to reduce the 
risk of acute urinary retention and surgical treat-
ment, and a  further 3.0% of urologists expect 
prostate size reduction.
The EAU guidelines recommend: “… 5a-reduc-
tase inhibitors (5ARIs) should be offered to men 
who have moderate-to severe lower urinary tract 
symptoms and enlarged prostates (> 40 ml) or el-
evated prostate specific antigen concentrations 
(> 1.4–1.6 µg/l). 5ARIs prevent disease progression 
with regard to acute retention and need for sur-
gery... 5ARIs reduce LUTS (IPSS) by approximately 
15–30%, decrease prostate volume by approx-
imately 18–28% and increase Qmax by approxi-
mately 1.5–2.0 ml/s in patients with LUTS due to 
prostatic enlargement… The guidelines commit-
tee is unable to make specific recommendations 
about phytotherapy of male LUTS, because of the 
heterogeneity of the products and the method-
ological problems associated with meta-analy-
ses…. Combination treatment with a1-blockers 
and 5ARIs should be offered to men with moder-
ate-to-severe LUTS, enlarged prostates (> 40 ml), 
and reduced Qmax…”
When prescribing 5ARI, respondents expected 
to reduce size of the prostate, decrease the risk of 
acute urinary retention, and improve the maximal 
urinary flow rate, as well as LUTS. However, only 
45.2% of urologists correctly anticipated that the 
size of the gland would be reduced by 15–25%, 
53.3% of doctors knew that the medication would 
improve symptoms by 15–30%, and 55.6% of re-
spondents relied on the aforementioned drug to 
increase the maximal urinary flow rate by 1.5–
2.0 ml/s.
Almost all urologists (84.4%) chose a-blockers 
as the first line treatment option in men with LUTS 
and a prostate size < 40 cc, whereas others pre-
scribed 5ARI monotherapy, a-blockers with 5ARIs, 
phytotherapy, or muscarinic receptor antagonists 
(Figure 2). a-Blockers were the preferred first line 
treatment option in men with LUTS and prostate 
size > 40 cc, as per the opinion of 48.9% of respon-
dents, whereas 17.1% chose 5ARI monotherapy, 
and 29.6% prescribed alpha blockers with 5ARIs 
as the primary management (Figure 3). 
The EAU guidelines recommend: “…Muscarinic 
receptor antagonists (MRA) might be considered 
in men with moderate to severe LUTS, who have 
predominantly bladder storage symptoms. Cau-
tion is advised in men with bladder outlet obstruc-
tion… Increase of PVR urine in men without BOO is 
minimal and not significantly different compared 
to placebo…”
Muscarinic receptor antagonists as an accept-
able treatment option for storage LUTS was used 
by 83.7% of urologists. Additionally, 34.8% of 
doctors would consider PVR and prescribe MRA 
if post-void residual urine volume was less than 
150 ml, whereas 9.4% would prescribe that medi-
cation regardless of PVR urine volume.
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The EAU guidelines recommend: “…phosphodi-
esterase type 5 inhibitors (PDEI-5) reduce moder-
ate to severe male LUTS… To date, only tadalafil 
5 mg once daily has been officially licensed for the 
treatment of male LUTS, with or without erectile 
dysfunction. Therefore, only tadalafil should be 
used clinically for the treatment of male LUTS…”
Among 135 urologists participating in the sur-
vey, only 10.4% identified tadalafil as the only 
phosphodiesterase type 5 inhibitor licensed for 
the treatment of male LUTS in Europe. In addition, 
49.6% of respondents answered that sildenafil, 
tadalafil or vardenafil could be used, whereas 
sildenafil or vardenafil were identified as the only 
PDEI-5 licensed for treatment by 36.3% and 3.7% 
of doctors, respectively.
The EAU guidelines recommend: “…Refractory 
urinary retention, recurrent urinary infection, re-
current hematuria refractory to medical treatment 
with 5ARIs, renal insufficiency due to BPE/BPO, and 
bladder stones are considered strong indications 
for surgery… Monopolar TURP is the current surgical 
standard procedure for men with prostate sizes of 
30–80 ml and moderate-to-severe LUTS secondary 
to BPO. Monopolar TURP provides subjective and 
objective improvement rates superior to medical or 
minimally invasive treatments. However, the mor-
bidity of monopolar TURP is higher than for bipolar 
TURP, or other minimally-invasive procedures…”.
Pharmacotherapy preceded surgical treatment 
in 80% of cases. However, only 46.4% of urologists 
found renal insufficiency due to benign prostat-
ic obstruction to be an indication for immediate 
operative procedure without commencing medi-
cal therapy. Among urologists who completed the 
survey, 58.8% would choose transurethral resec-
tion of the prostate (TURP) as a preferred treat-
ment option, while 37.8% would perform laser 
vaporization of the prostate, and only 3.7% would 
perform open prostatectomy.
Figure 3. The preferred first line treatment option in men with LUTS and prostate size > 40 cc
LUTS – Lower urinary symptoms, cc – cubic centimeters, 5ARI – 5a-reductase inhibitors, MRA – muscarinic receptor antagonists.
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Figure 2. The preferred first line treatment option in men with LUTS and prostate size < 40 cc
LUTS – Lower urinary symptoms, cc – cubic centimeters, 5ARI – 5a-reductase inhibitors, MRA – muscarinic receptor antagonists.
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Statistical analysis
Overall, the median (quartile 1 (Q1); quartile 
3 (Q3)) frequency of correct answers was 65.0% 
(58.0%; 69.0%). The median (Q1; Q3) frequency 
of correct answers regarding diagnosis and treat-
ment of LUTS was 67.0% (56.0%; 73.0%) and 
65.0% (55.0%; 73.0%), respectively. As there was 
only one question about the diagnosis of OAB, and 
another one about the treatment of OAB, no sta-
tistical analysis was performed. However, 16.3% 
and 80.7% of respondents, respectively, answered 
correctly for those questions. 
Figure 4 presents the percentage of doctors 
who passed or failed any of the four domains of 
the test (diagnosis of LUTS, treatment of LUTS, di-
agnosis of OAB, treatment of OAB) based on the 
cut-off value of 60% of correct answers for pass-
ing the test for diagnosis and treatment of LUTS 
test domains and one correct answer for ques-
tions regarding diagnosis of OAB and one about 
OAB treatment.
Analysis of the association of availability and 
acceptance of the 2013 EAU guidelines with an-
swers to the questions within the four tested do-
mains of knowledge showed no pattern. There 
was only one question about the treatment of 
mild-to-moderate LUTS, associated with accep-
tance. There were 60 doctors who accepted the 
EAU guideline recommendations and answered 
the above question correctly; only 3 respondents 
who accepted the EAU guideline recommenda-
tions provided an incorrect answer to the ques-
tion (p = 0.037). As penetration of the EAU 2013 
guidelines was 100%, no analysis was performed 
for the association with answers.
A multivariate regression model to investigate 
whether there was a  correlation between time 
since having completed the residency program in 
urology, number of urological journals to which 
the respondent subscribed, number of national 
and international conferences attended, as well as 
being an EAU member and the correct and incor-
rect answers was performed. There was a positive 
correlation with regards to correct answers given 
in the survey and doctors’ participation in interna-
tional congresses (p = 0.018, r = 0.181). However, 
no other correlation was found.
Basket analysis was performed to determine 
answer patterns in order to determine whether 
respondents who failed to answer at least 60% 
of questions correctly for one knowledge domain 
provided incorrect answers to more than 40% 
of the questions in the remaining domains. The 
strongest association was found for those who 
failed to answer the questions regarding diag-
nosis of LUTS and a  question about diagnosing 
OAB correctly (support = 27.41%, confidence = 
86.05%) and for those who incorrectly answered 
the questions regarding both diagnosis and treat-
ment of LUTS, and a question about treatment of 
OAB (support = 11.11%, confidence = 88.24%). 
Table I gives details of the analyzed associations.
Discussion
From these results, it is clear that the majori-
ty of the EAU guidelines on management of male 
lower urinary tract symptoms, including benign 
prostatic obstruction, reflect current practice 
among urologists practicing in Poland. However, 
there have been several key areas where their 
Figure 4. Percentage of doctors who passed or failed any of the four domains of the test (diagnosis of LUTS, treat-
ment of LUTS, diagnosis of OAB, treatment of OAB)
OAB – Overactive bladder, LUTS – lower urinary symptoms; the cut-off value for passing the test is 60% of correct ansewrs for 
diagnosis and treatment of LUTS test domain and one correct answer for questions regarding diagnosis of OAB and one about 
OAB treatment.
Treatment of OAB
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management differed substantially from guideline 
recommendations. 
The first concerned the initial assessment of 
a man with LUTS. The EAU guidelines recommend 
a systematic diagnostic work-up, which should in-
clude history, validated symptom questionnaires 
(e.g. IPSS), physical examination, urinalysis, USS of 
the prostate, bladder and kidneys, uroflowmetry 
and USS measurement of post-void residual urine 
volume, and bladder diary, in the case of urinary 
frequency, or nocturia [4]. Despite doctors’ rec-
ognition of the importance of a thorough history, 
44.0% of respondents did not routinely quantify 
LUTS. In addition, 40.0% of urologists did not use 
a bladder diary and a  further 8.1% would use it 
only to evaluate the treatment outcome. As to the 
respondents who did not complete the IPSS, the 
validated questionnaire is a time-consuming tool 
that offers little advantage in the treatment de-
cision-making process. However, the accumulated 
evidence in the literature suggests that the IPSS is 
not a reliable diagnostic tool for LUTS, but serves 
merely as a measure of LUTS after the diagnosis 
is established [5, 6]. Therefore, its significance in 
the management of men with LUTS cannot be un-
derestimated.
Prevalence of nocturnal polyuria, defined as 
nocturnal urine volume greater than 33% of 24-
hour volume, can reach up to 89% of men with 
LUTS [7]. Diagnosis of this cause of nocturia can 
be made simply based on the bladder diary [8]. 
Hence, the initial diagnostic work-up of a patient 
presenting with nocturia or polyuria should in-
clude the completion of a frequency-volume chart. 
Similarly to the underuse of the IPSS and blad-
der diary during the initial assessment of patients 
with LUTS, respondents would commonly not per-
form urinalysis and blood analysis (serum creati-
nine) tests, as well as uroflowmetry. These inves-
tigations were only performed by 3.0%, 0.7% and 
1.5% of urologists, respectively. This may have im-
plications for the diagnosis and success of treat-
ment of men with LUTS. It is not clear why these 
mandatory tests are rarely carried out by the re-
spondents. The reported practice was not due to 
lack of penetration, nor availability or acceptance 
of the 2013 EAU guideline recommendations. The 
financial issue should also be disregarded, as 
those tests are, in fact, inexpensive and readily 
available. 
In this survey, 22.2% of respondents would con-
sider prostate size as an indication for treatment. 
Moreover, 42.2% of urologists believe that the size 
of the gland corresponds with the bladder outlet 
obstruction. There is a large body of evidence indi-
cating that prostate size does not correspond with 
bladder outlet obstruction, and is completely un-
important in determining the need for treatment 
of male patients with LUTS [9, 10]. Unfortunately, 
it is not known why size of the prostate is con-
sidered to be an indication for treatment of male 
LUTS and why many of the doctors believed that it 
corresponds with bladder outlet obstruction. The 
reported notions were not due to insufficient pen-
etration, availability, or acceptance of current EAU 
guidelines, as none of those parameters were as-
sociated with a failure to provide corrects answers.
In our study, almost all of the urologists com-
menced pharmacotherapy in patients with mod-
erate or severe lower urinary tract symptoms. 
However, only 31.9% of urologists explained to 
their patients that the aim of the treatment is to 
reduce LUTS, whereas 51.9% told the men that the 
therapy would prevent surgical intervention, and 
a further 14.1% gave delay of surgery as a reason 
for introducing a  medical approach. It is unclear 
why respondents offered limited information to 
their patients. However, it seems unlikely to be re-
lated to lack of awareness about the mechanisms 
of action of the most commonly prescribed med-
ications, as the majority of respondents correctly 
identified the expected effects of the most fre-
quently prescribed medications.
The statements concerning the treatment of 
LUTS with phosphodiesterase type 5 inhibitors 
were quite interesting. Among 135 urologists 
participating in the survey, only 10.4% identified 
tadalafil as the only PDEI-5 licensed for treatment 
Table I. Basket analysis of incorrect answers
Variable 1 Variable 2 Support (%) Confidence (%)
If D1 fails then D2 fails 12.59 39.53
If D3 fails then D4 fails 17.04 20.35
If D1 fails then D3 fails 27.41 86.05
If D1 + D2 fails then D3 fails 11.11 88.24
If D1 + D2 fails then D4 fails 2.96 23.53
If D1 + D2 + D3 fails then D4 fails 2.96 26.67
Key: D1 = diagnosis of lower urinary tract symptoms, D2 = treatment of lower urinary tract symptoms, D3 = diagnosis of overactive 
bladder, D4 = treatment of overactive bladder.
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of male LUTS in Europe. The introduction of PDEI-5 
for the treatment of moderate-to-severe storage 
and voiding lower urinary tract symptoms has 
been a  relatively novel approach [11, 12]. This 
most likely explains the lack of awareness regard-
ing phosphodiesterase type 5 inhibitor use in 
medical management of male LUTS.
In this study, no association of penetration, 
availability or acceptance of the 2013 EAU guide-
lines with answers to the questions was found, 
except for one question regarding treatment of 
mild-to-moderate LUTS. Interestingly, in a  multi-
variate regression model, only one weak correla-
tion between potential factors improving access 
to knowledge and the doctors’ answers was iden-
tified. Attendance at international, but not na-
tional, congresses correlated with correct answers 
(p = 0.018, r = 0.181 and p = 0.406, r = 0.021, re-
spectively). This finding was enhanced by the fact 
that 45.9% of respondents participated in an in-
ternational meeting only once every several years, 
45.9% of doctors attended a  congress annually, 
and only 8.2% of urologists took part in 1 to 3 in-
ternational meetings every year. However, 74.9% 
of respondents declared having been present at 
1 to 3 national congresses per year, 20.7% of 
doctors participated in 4 to 6 domestic meetings 
annually, 3.7% of specialists participated once ev-
ery several years, and only one urologist (0.7%) 
participated less than once every 10 years. How-
ever, this may reflect the fact that the 2013 EAU 
guidelines were introduced in March 2013 and 
the study was carried out between April and June 
2013. Within that period of time, several interna-
tional meetings took place, including the EAU an-
nual congress, whereas only 3 national meetings 
that were dedicated exclusively to uro-oncology 
were organized. On the other hand, as the 2013 
EAU guidelines are an update of the previous ver-
sions and therefore cover the majority of the rec-
ommendations that have been in place for a few 
years, an insufficient amount of time dedicated 
for discussion of current EAU recommendations at 
domestic meetings as well as their quality need to 
be considered.
In an attempt to identify answer patterns, 
a  basket analysis was performed. This showed 
that there were not many respondents who pro-
vided less than 60% of correct answers to more 
than one tested knowledge domain. The strongest 
relation was seen among those who incorrectly 
answered questions regarding diagnosis of LUTS 
and OAB. 27.41% of doctors incorrectly answered 
at least 60% of questions about diagnosis of both 
LUTS and OAB, and 86.05% of urologists who pro-
vided incorrect answers to more than 40% of the 
questions regarding diagnosis of LUTS provided 
incorrect answers to the question about OAB di-
agnosis, concurrently. 
This survey provides useful insight into cur-
rent strategies practiced by Polish urologists 
in the diagnosis and management of male pa-
tients with lower urinary tract symptoms. The 
discrepancies observed between the 2013 EAU 
guideline recommendations and strategies in di-
agnosis and management of male LUTS provide 
a benchmark of practice patterns among Polish 
urologists. However, some urologists’ practice 
patterns should be altered to improve the stan-
dard of care. Further education based on the 
recent EAU recommendations needs to be con-
tinued. Current guidelines on management of 
male LUTS need to be discussed more often at 
national meetings and the results of this practice 
should then be audited. Although this study did 
not show a  correlation between translation of 
the 2013 EAU guidelines into Polish and answers 
provided by the doctors who participated in the 
survey, it seems that translation of the guidelines 
could be of benefit to at least 80% of doctors 
who are not sufficiently familiar with the English 
language.
This survey is not an epidemiologic study and, 
thus, it is subject to bias and limitations associ-
ated with these study designs. Physicians who 
completed the survey elected to participate, so 
they may not be a representative sample of Polish 
urologists. Moreover, the data used in this survey 
are based solely on the awareness of respondents, 
and not on real world scenarios. Therefore, this 
survey could bear a certain degree of subjectivity. 
Further, all data were collected through self-ad-
ministered questionnaires. This could contribute 
to sampling error, as different survey modes have 
different sampling errors, response rates, data 
completeness, and measurement errors [13]. 
In conclusion, this study provides insight into 
current strategies used by Polish urologists in the 
diagnosis and management of male patients with 
lower urinary tract symptoms. Although there is 
a significant degree of adherence to the 2013 EAU 
guidelines, some discrepancies between urolo-
gist practice and the recommendations regarding 
diagnosis and treatment of male LUTS do exist. 
Obtained data provide valuable benchmarks and 
identify possible interventions that may be ad-
dressed in order to improve the standard of care 
in this population of patients.
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Appendix 1
Part one:
1. How long have you been practicing urology 
since completing your residency?
– < 5 years,
– 5–10 years,
– 10–15 years,
– > 15 years.
2. The type of healthcare sector you work for is:
– private,
– public.
3. Do you see your patients in an outpatient clin-
ic as well as on the wards?
– Yes,
– No.
4. Describe your workplace setting:
– rural area or small town (population less 
than 50,000),
– town (population between 50,000 and 
100,000),
– city (population greater than 100,000).
5. Can you describe the number of daily specialty 
consultations you usually deliver?
– < 10,
– 10–20,
– > 20.
6. To how many specialty journals are you cur-
rently subscribing?
– 0,
– 1,
– 2,
– 3,
– > 3.
7. How often do you attend any national confer-
ences or symposia?
– Occasionally, every few years,
– 1–3 times per year,
– 4–6 times per year,
– 7–10 times per year,
– > 10 times per year.
8. How often do you attend any international 
conferences or symposia?
– Occasionally, every few years,
– At least once a year,
– 1–3 times per year,
– > 3 times per year.
9. How do you keep your specialty knowledge 
up-to-date?
– Books and manuscripts,
– Urology journals,
– Conference proceedings,
– Discussions with colleagues,
– Other.
10. Are you an EAU member?
– Yes,
– No.
11. Are you aware that a new 2013 edition of the 
EAU guidelines on the management of male 
lower urinary tract symptoms (LUTS), includ-
ing benign prostatic obstruction (BPO), has 
recently been published?
– Yes,
– No.
12. Have you received the EAU 2013 guidelines, 
because you are an EAU member?
– Yes,
– No.
13. If you are NOT an EAU member, have you still 
received the EAU 2013 guidelines?
– Yes, the latest version from EAU members,
– Yes, electronic version,
– No.
14. Do you think that the Polish Urological Asso-
ciation ought to translate all available EAU 
guidelines?
– Yes, all,
– Yes, but not all (if so please describe which 
ones exactly……….),
– No, I do not mind reading the guidelines in 
English.
15. How useful do you find the EAU guidelines in 
your practice?
– I use them regularly,
– I only use them every so often,
– I do not find them useful or transferrable to 
Polish standards of practice.
16. Do you follow the EAU 2013 guidelines in your 
daily practice?
– Always,
– Never,
– Sometimes.
Part II: Diagnosis of lower urinary tract symp-
toms (LUTS) and overactive bladder (OAB)
1. In your patients presenting with LUTS, to 
which of the following phases are the symp-
toms they predominantly complain of related?
– Storage,
– Voiding,
– Post-micturition.
2. As per the literature, which two LUTS are con-
sidered by the patients as the most bother-
some?
– Nocturia,
– Hesitancy,
– Urgency,
– Difficulty passing urine,
– Interrupted urine flow,
– Post-micturition dribble – wetting under-
wear,
– Incomplete bladder emptying,
– Weak stream of urine.
3. In patients with no suspicious findings on dig-
ital rectal examination, and no additional in-
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vestigations available, your initial assessment 
tool includes which of the following?
– USS,
– Uroflowmetry,
– PSA,
– Serum creatinine or eGFR,
– Mid stream urinalysis,
– Urine culture and sensitivity,
– Micturition diary,
– IPSS questionnaire.
4. With regards to the International Prostate 
Symptom Score questionnaire (IPSS) please 
choose one of the options below:
– It is always completed by a patient at the 
first clinical appointment,
– It is handed over to a patient to complete 
later at home and to bring back at the next 
visit,
– I only use it occasionally.
5. What maximum urine flow is the most sugges-
tive of bladder outlet obstruction (BOO)?
– < 5 ml/s,
– < 10 ml/s,
– < 15 ml/s.
6. Does the size of the prostate influence your 
clinical judgment?
– Yes, it is an indication for treatment,
– Yes, but only if associated with BOO,
– Yes, but only if associated with LUTS,
– Yes, as this can affect the choice of surgical 
technique,
– It should not affect the clinical judgment 
with regards to treatment.
7. Do you recommend using a bladder diary to 
your patients?
– Almost never,
– To each patient with BPH,
– Only to patients with LUTS during storage 
phase,
– Only to assess the therapeutic response.
8. Which of the investigations do you think is re-
quired in order to confirm that BOO is caused 
by BPH, and that LUTS are associated with the 
voiding phase?
– USS,
– Uroflowmetry,
– Urethrography,
– Complete urodynamic assessment,
– Other (describe).
9. Which of the following USS findings may sug-
gest BOO?
– Upper urinary tract dilatation,
– Post-micturition residual urine volume  
> 50 ml,
– Post-micturition residual urine volume  
> 100 ml,
– Post-micturition residual urine volume  
> 150 ml,
– Prostate size,
– Large middle lobe of the prostate,
– Bladder wall thickness,
– Bladder diverticula,
– Bladder stone.
10. The constellation of symptoms described as 
overactive bladder is diagnosed based on:
– Predominance of LUTS with urgency during 
storage phase,
– Exclusion of other disorders presenting with 
LUTS (i.e. UTI, CIS, radiation cystitis),
– Urodynamic investigation,
– All of the above.
Part III: Treatment of LUTS and OAB
1. What is your next step following the history 
and investigations of confirmed diagnosis of 
mild-to-moderate LUTS?
– Watchful waiting,
– Lifestyle modification and diet: cutting the 
amount of fluids, coffee, alcohol, altering 
the time of the day when fluids and medi-
cations should preferably be taken, bladder 
training, treating constipation,
– Implementation of phytotherapy (herbal 
medicines),
– Commencing pharmacotherapy,
– Further management depends on patient’s 
individual preferences,
– Other (describe).
2. What would be your next management step in 
patients with severe LUTS with the majority 
of symptoms during the voiding phase?
– Pharmacotherapy,
– Surgery,
– Other (describe).
3. Which of the following indications for surgery 
do you find the most relevant? 
– Prostate size,
– Storage phase LUTS,
– Voiding phase LUTS,
– Post-micturition phase LUTS,
– Post-voiding residual volume > 150 ml,
– Maximum urinary flow < 10 ml/s,
– Treatment of resistant urinary tract infec-
tions (UTIs).
4. With regards to BPH treatment, when do you 
obviate medical treatment in favor of surgery 
as the first line treatment?
– Very large prostate,
– Treatment of refractory UTIs,
– Acute urinary retention,
– Renal failure,
– All of the above.
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5. When prescribing medical treatment for LUTS 
to a patient, how do you justify your choice 
over another treatment option(s)?
– To postpone surgical treatment,
– To prevent surgical treatment,
– You concentrate on the treatment of LUTS 
rather than BPH progression,
– Other (describe).
6. Which a1-blocker do you tend to use the most?
– Doxazosin,
– Tamsulosin,
– Alfuzosin,
– Terazosin,
– Other (which one).
7. When using a1-blockers, which of the follow-
ing are you expecting?
– Amelioration of LUTS,
– Improvement in uroflow,
– Reduction in prostate size,
– Preventing progression, thereby reducing 
the risk of acute urinary retention and 
possible operative treatment,
– All of the above.
8. When would you decide for a1-blocker mono-
therapy?
– Prostate volume < 30 ml, severe LUTS asso-
ciated with storage phase,
– Prostate volume < 30 ml, moderate LUTS as-
sociated with storage and voiding phases,
– Prostate volume > 100 ml, moderate LUTS 
associated with storage and voiding phases,
– In every patient with LUTS as the first line 
treatment.
9. With regards to the 5a-reductase inhibitors 
(5ARIs), which of the following can you ex-
pect?
– Amelioration of LUTS,
– Improvement in urinary flow,
– Reduction in prostate size,
– Preventing progression, thereby reducing 
the risk of acute urinary retention and 
possible operative treatment,
– All of the above.
10. By how much can the 5ARIs reduce prostate 
volume?
– 5–10%,
– 10–15%,
– 15–25%,
– 25–35%.
11. By how much can the 5ARIs reduce LUTS as 
per the IPSS?
– 10–15%,
– 15–30%,
– 30–40%.
12. Using the 5ARIs, by how much can the maxi-
mum urinary flow be improved?
– 1.0–1.5 ml/s,
– 1.5–2.0 ml/s,
– 2.0–3.0 ml/s,
– 3.0–3.5 ml/s.
13. Which class of medications do you choose for 
patients with prostate volume of < 40 cc and 
mild to severe LUTS?
– a1-Blockers,
– 5ARIs,
– Combination of a1-blocker and 5ARI,
– Antimuscarinics,
– Herbal remedies.
14. Which of the following classes of drugs do you 
use in men with prostate volume > 40 cc and 
mild LUTS?
– a1-Blockers,
– 5ARIs,
– Combination of a1-blocker and 5ARI,
– Antimuscarinics,
– Herbal remedies.
15. It has been shown that in men with concurrent 
erectile dysfunction and LUTS, who are treat-
ed with a combination of a1-blocker and 5ARI, 
which type of 5 phosphodiesterase inhibitor 
can replace 5ARI?
– Sildenafil,
– Tadalafil,
– Vardenafil,
– All of the above.
16. When do you use antimuscarinics?
– Patients with voiding phase LUTS,
– Patients with storage phase LUTS,
– When post-voiding residual urine volume 
exceeds 150 ml,
– Regardless of the residual volume.
